Zanolimumab
As of the edition of 20 October 2026, Zanolimumab is an antibody: stopped in 2012; acts on CD4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2012
- Kind
- Antibody
- Registered trials
- 6, 3 stopped early
- Disease areas
- Cancer; Immune system; Blood and lymph; Skin and connective tissue; Bones, joints and muscles; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Zanolimumab.
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD4 | T-cell surface glycoprotein CD4 | P01730 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 2 | 0 | 1 |
| Phase 3 | 3 | 1 | 0 | 2 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merus | Lead sponsor of trials | 2002 to now |
| Emergent Product Development Seattle | Lead sponsor of trials | 2005 to now |
| Emergent Biosolutions | Lead sponsor of trials | 2005 to now |